"A combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, has been observed very rarely following vaccination with Covid-19 Vaccine Janssen. A causal role of the vaccine is considered plausible."
This is reported in an "important information note agreed with European and Italian regulatory activities", written by Janssen, the Johnson & Johnson pharmaceutical company, and published on the portal of the Italian Medicines Agency (Aifa).
These cases, as known, "occurred within the first three weeks after vaccination and mainly in women under the age of 60" and in "this phase no specific risk factors have been identified". Thrombosis in combination with thrombocytopenia requires specialized clinical management. For this, underlines the note, "health professionals must pay attention to the signs and symptoms of thromboembolism and / or thrombocytopenia" in subjects vaccinated with the Jansssen vaccine and the latter "must be instructed to consult a doctor immediately if they develop symptoms of thromboembolism. and / or thrombocytopenia, after vaccination "(ANSA).